Nebula Genomics
A personal genomics company offering whole-genome sequencing and genomic data services.
Last updated November 4, 2026
AI crawler reads
5requests
1companies- Anthropic5
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Nebula Genomics is a personal genomics company based in San Francisco, California. The company was established in 2018 by geneticist George Church and has focused on making high-coverage whole-genome sequencing more accessible to consumers. Its proposition combines laboratory sequencing with tools intended to give individuals greater control over their genomic information and, where they choose, enable participation in research or other forms of genomic data sharing. The company emerged during a period in which direct-to-consumer genetic testing was expanding beyond ancestry and limited health-trait reports toward more comprehensive sequencing. Rather than concentrating primarily on genotyping a selected set of genetic markers, Nebula promoted whole-genome sequencing, which examines a much larger portion of a person's DNA. In August 2018, it announced a $4.3 million seed financing round led by Khosla Ventures. In 2019, Nebula received the Best-in-Show award at the SXSW Pitch competition. In February 2020, Nebula began offering high-coverage whole-genome sequencing internationally at a stated price of $299. The service was linked to a subscription product called Nebula Explore, which provided access to genomic reports and related interpretation or research-oriented features. Nebula's public positioning emphasized affordability, transparency, and privacy-preserving data use. The company also described work on technologies intended to support controllable genomic data sharing, including blockchain-related approaches and methods for analyzing genomic datasets while reducing unnecessary exposure of identifying information. Nebula's operating model and privacy claims have attracted scrutiny because genomic information is unusually sensitive and difficult to make permanently anonymous. Publicly described policies allowed the creation and use of de-identified or aggregated datasets and permitted disclosure in certain circumstances, including legal demands and measures intended to protect the service or its users. Critics have noted that genetic information can potentially be re-identified even after conventional anonymization, and that law-enforcement requests, security vulnerabilities, and the technical difficulty of protecting whole-genome data create risks that cannot be eliminated solely through encryption or distributed-ledger technology. The company's relationship with BGI Group has also been a significant subject of public discussion. In February 2020, Nebula announced a partnership under which saliva samples were sent to BGI laboratories in Hong Kong for sequencing. The arrangement was presented as a way to lower the cost of whole-genome testing. Questions about the handling and possible downstream use of consumer genetic information were heightened by wider controversy surrounding BGI and by George Church's longstanding scientific relationship with the organization. Nebula later stated in company FAQs that samples were sequenced in Europe, although publicly available descriptions of the sequencing location changed or became less specific over time. On August 11, 2021, ProPhase Labs announced that its newly formed subsidiary, ProPhase Precision Medicine, had agreed to acquire Nebula Genomics for approximately $14.6 million in a combination of cash and ProPhase Labs common stock. The acquisition placed Nebula within ProPhase's broader medical-science and precision-medicine strategy. In 2024, ProPhase expanded its genomics activities by forming DNA Complete, Inc., a direct-to-consumer genetic-testing subsidiary that launched in November 2024. ProPhase said DNA Complete used Nebula's laboratory, alongside other laboratories, for sample sequencing. Nebula has also faced litigation concerning genetic privacy. In October 2024, a proposed class action, Portillo v. Nebula Genomics, Inc., was filed in the United States District Court for the Northern District of Illinois. The complaint alleged that genetic information was shared with third parties without the written consent required by the Illinois Genetic Information Privacy Act and named technology companies among the defendants. The case was transferred to the United States District Court for the District of Massachusetts under a forum-selection clause in Nebula's terms of use. The Illinois court's transfer-related ruling noted the privacy-policy disclosures at issue. After transfer, the technology companies were reportedly no longer provisionally participating as defendants, and the matter remained at the pleading stage as of October 2025, with Nebula seeking dismissal. The allegations remain contested and do not establish a final finding of liability.
History
Nebula Genomics was founded in 2018 in San Francisco by geneticist George Church and other co-founders whose identities are not specified in the supplied reference material. The company entered the consumer genomics market with a focus on whole-genome sequencing rather than the more limited genotyping commonly associated with early direct-to-consumer genetic-testing services. Its stated objective was to make comprehensive sequencing less expensive while giving individuals more visibility and control over the use of their genomic information. In August 2018, Nebula announced a $4.3 million seed financing round led by Khosla Ventures. The funding supported the development of its sequencing service and data platform. The company's technology proposition combined laboratory sequencing with software for genomic exploration, research participation, and data-sharing controls. Nebula also described privacy-preserving analysis as an important area of development, including the use of blockchain-related mechanisms to help users manage access to genomic information. Nebula gained early public recognition in 2019 when it won the Best-in-Show award at the SXSW Pitch competition. In February 2020, it introduced a high-coverage whole-genome sequencing service priced at $299 and made the offering available internationally. Customers were also required to subscribe to Nebula Explore, which provided access to reports and other genomic services. The price was positioned as a substantial reduction from the historical cost of whole-genome sequencing. On February 18, 2020, Nebula announced a sequencing partnership with BGI Group. Under the arrangement described in public accounts, saliva samples sent to Nebula were forwarded to BGI laboratories in Hong Kong for sequencing. Nebula presented the partnership as a way to achieve lower prices. The relationship attracted scrutiny because BGI has been the subject of broader controversies involving genetic-data collection and because George Church had served on BGI's scientific advisory board and collaborated with BGI-linked researchers. Later Nebula FAQs stated that samples were sequenced in Europe, while subsequent public FAQs did not provide an equally specific location. This created continuing questions about the geographic handling of customer samples. Privacy has remained central to the company's public profile. Nebula's privacy materials described the possible creation of de-identified and aggregated datasets and allowed such datasets to be used or disclosed for purposes permitted by law. The policies also recognized that personal or genetic information could be processed in response to warrants, subpoenas, governmental orders, or other legal demands. Observers have emphasized that DNA is inherently identifying and that genomic datasets can potentially be re-identified even after direct identifiers are removed. Concerns have also included cybersecurity, the difficulty of encrypting complete genomes, and the possibility of law-enforcement access or unauthorized disclosure. On August 11, 2021, ProPhase Labs announced that its recently created subsidiary, ProPhase Precision Medicine, Inc., would acquire Nebula Genomics for approximately $14.6 million through a mixture of cash and ProPhase common stock. The transaction brought Nebula into ProPhase's precision-medicine and medical-technology group. Nebula subsequently formed part of ProPhase's wider genomics strategy rather than operating solely as an independent venture-backed company. In 2024, ProPhase created DNA Complete, Inc., a new genomics subsidiary. DNA Complete launched in November 2024 as a direct-to-consumer genetic-testing service. ProPhase stated that DNA Complete used Nebula's laboratory, in addition to other laboratories, to sequence customer samples, indicating that Nebula's laboratory capabilities continued to support the parent company's consumer genomics expansion. In October 2024, Portillo v. Nebula Genomics, Inc. was filed as a proposed class action in the U.S. District Court for the Northern District of Illinois. The complaint alleged violations of the Illinois Genetic Information Privacy Act based on the claimed disclosure of sensitive genetic information, including information relating to disease predisposition and hormone levels, to third parties without written consent. Meta Platforms, Google, and Microsoft were named in the initial litigation. The case was transferred to the U.S. District Court for the District of Massachusetts pursuant to a forum-selection clause in Nebula's terms of use. The Illinois court observed that the plaintiff would have been aware of the company's privacy-policy language concerning third-party data use. Following transfer, the technology companies were reportedly provisionally no longer parties to the case. As of October 2025, the action remained at the pleading stage and Nebula had filed a motion to dismiss. No final liability determination is established by the supplied materials.
- 2024
DNA Complete established and launched
[1]ProPhase formed DNA Complete as a genomics subsidiary; the direct-to-consumer service launched in November 2024 and used Nebula's laboratory among its sequencing resources.
- 2024
Genetic-privacy class action filed
[1]Portillo v. Nebula Genomics was filed in Illinois, alleging unauthorized disclosure of genetic information under the Illinois Genetic Information Privacy Act.
- 2021
Acquired by ProPhase Labs
[1]ProPhase Labs announced the acquisition of Nebula through ProPhase Precision Medicine.
- 2020
High-coverage sequencing service introduced
[1]Nebula began offering international high-coverage whole-genome sequencing at a stated price of $299, alongside Nebula Explore.
- 2020
BGI sequencing partnership announced
[1]Nebula announced a partnership involving sequencing of customer saliva samples at BGI laboratories in Hong Kong.
- 2019
SXSW Pitch award
[1]Nebula won the Best-in-Show award at SXSW Pitch.
- 2018
Company founded
[1]Nebula Genomics was co-founded in San Francisco by geneticist George Church.
- 2018
Seed financing announced
[1]The company announced a $4.3 million seed round led by Khosla Ventures.
Products and positioning
Affordable, consumer-controlled whole-genome sequencing with an emphasis on genomic privacy, transparency, and research access.
Personal genomics · 2020
High-coverage whole-genome sequencing
Nebula's principal consumer offering is whole-genome sequencing, intended to examine substantially more of an individual's DNA than a targeted genotyping test. In February 2020, the company announced an international high-coverage service at a stated price of $299. The service was designed to generate a comprehensive genomic dataset that could support health-related interpretation, personal exploration, and optional research participation.
Genomic interpretation subscription · 2020
Nebula Explore
Nebula Explore is the subscription component associated with the company's sequencing service. It provides access to genomic exploration and related reports or research-oriented features after sequencing. The subscription requirement formed part of Nebula's business model when the company introduced its $299 high-coverage whole-genome sequencing offering.
Bioinformatics and data infrastructure
Genomic data-sharing and privacy technology
Nebula has developed and described technologies intended to make genomic data sharing more controllable and transparent. Its stated research direction includes privacy-preserving analysis of genomic datasets and blockchain-related approaches for managing security and access. These technologies address the challenge of enabling research use while limiting unnecessary exposure of personally identifying genomic information.
Controversies
2024
Genetic-data sharing litigation
A proposed class action alleged that Nebula shared sensitive customer genetic information with third parties without legally required written consent. The allegations remained unresolved and were being contested in litigation.
2020
Questions surrounding the BGI sequencing partnership
Nebula's arrangement to send saliva samples to BGI laboratories in Hong Kong prompted scrutiny over sample location, genetic-data governance, and the wider controversies associated with BGI. Nebula described the partnership as a cost-reduction measure. Later statements referring to European sequencing, followed by less specific public information, added uncertainty about the sequencing locations.
Marketing campaigns
- 2019SXSW Pitch
United States
Nebula entered the SXSW Pitch competition as part of its effort to raise visibility for consumer whole-genome sequencing and privacy-oriented genomic data services.
Outcome. The company won the Best-in-Show award.
Brand decisions
2024
Supported the launch of DNA CompleteProduct launchBackground
ProPhase Labs expanded its genomics segment after acquiring Nebula and established DNA Complete as a new direct-to-consumer testing subsidiary.
Action taken
DNA Complete launched in November 2024 and used Nebula's laboratory, together with other laboratories, for sample sequencing.
Aftermath
The launch extended ProPhase's consumer genomics footprint and gave Nebula's laboratory operations a role in a broader branded testing platform.
2021
Acquisition by ProPhase LabsM&ABackground
ProPhase Labs was expanding its medical-science and precision-medicine activities and had created ProPhase Precision Medicine as an acquisition vehicle.
Action taken
ProPhase Labs announced the purchase of Nebula Genomics for approximately $14.6 million in a combination of cash and ProPhase Labs common stock.
Aftermath
Nebula became part of ProPhase's precision-medicine group and later supplied laboratory capabilities for the parent company's DNA Complete consumer genomics initiative.
Announced acquisition value. Approximately $14.6 million (August 11, 2021)
2020
Set whole-genome sequencing price at $299Price changeBackground
Whole-genome sequencing had historically been too expensive for many consumers, and Nebula sought to broaden access through a lower advertised price.
Action taken
Nebula introduced high-coverage whole-genome sequencing internationally at a stated price of $299, while requiring access to the Nebula Explore subscription.
Aftermath
The pricing reinforced Nebula's affordability positioning but also intensified questions about laboratory practices, sequencing arrangements, and the potential commercial value of consumer genomic data.
2020
Partnered with BGI for sequencingStrategyBackground
Nebula sought to reduce the cost of whole-genome sequencing and announced a laboratory relationship with BGI Group.
Action taken
The company arranged for customer saliva samples to be sent to BGI laboratories in Hong Kong for sequencing, according to public descriptions of the partnership.
Aftermath
The partnership supported the company's low-cost sequencing proposition but became a focus of privacy, data-governance, and geographic-processing concerns.
Recent events
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nebula-genomics · Editorial policy · How profiles are compiled